Literature DB >> 16786041

Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness.

M Tischkowitz, A Gologan, H Srolovitz, M Khanna, W D Foulkes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786041      PMCID: PMC2360619          DOI: 10.1038/sj.bjc.6603228

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, We would like to give an update on a family with Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) that we have previously reported with germline truncating mutations in MSH2 (exon 8 deletion) and BRCA2 (542G>T) (Thiffault ). This was a 26-member kindred with five cases of colorectal cancer and five cases of breast cancer, all but one of the cancers occurring below the age of 45 years. We reported that one of the individuals who had been diagnosed with rectal cancer (III.10 in original pedigree) also had a keratoacanthoma. This type of skin lesion is seen in some families with MSH2 or, less commonly, MLH1 mutations when it is termed Muir–Torre Syndrome (MTS) (Ponti and Ponz de Leon, 2005). Immunohistochemistry (IHC) at the time showed normal MSH2 expression, so we felt that this family did not belong to the MTS group. Subsequently, the individual was diagnosed with two separate sebaceous carcinomas on each arm. Immunohistochemistry analysis of these lesions shows loss of MSH2 expression in both cases, one of which is shown in Figure 1, confirming that this is in fact an MTS family.
Figure 1

Sebaceous carcinoma: haematoxylin and eosin (× 100): multilobulated expansile intradermal tumour showing large polygonal cells with differentiation into sebaceous cells, altered nuclear/cytoplasmic ratio, evidence of apoptosis and high mitotic count. Insert: MSH2 immunohistochemical stain (× 400): Absence of nuclear staining for the MSH2 mismatch repair protein in the tumour cells (the tumour infiltrating lymphocytes show normal expression of MSH2).

This new development illustrates two points. Firstly the Lynch syndrome and MTS phenotypes are pleiotropic and Lynch syndrome can evolve into MTS in the same family. Lynch syndrome is usually suspected when the Amsterdam Criteria are fulfilled or the less-specific Bethesda guidelines are met. The individual described here had an anal canal squamous carcinoma, a cancer type not associated with Lynch syndrome, which was microsatellite stable. His father, who was an obligate MSH2 mutation carrier, had a rectal cancer which is also unusual (Hoogerbrugge ), and an astrocytoma, raising the possibility of overlap with another variant, Turcot syndrome. Although Turcot syndrome was classically thought of as a combination of brain tumours and polyposis and has been mainly associated with mutations in the APC gene (Galiatsatos and Foulkes, 2006), a minority are also due to mutation in the Lynch syndrome genes, particularly biallelic PMS mutation carriers (De Vos ). Secondly, the case emphasises the importance of continuing dermatological vigilance in MSH2 families. The same MSH2 mutations are found in both MTS and Lynch families (Ponti and Ponz de Leon, 2005), so it is not possible to predict which families are more likely to develop MTS. The sebaceous cancers in MTS are possibly less aggressive than sporadic types (Ponti and Ponz de Leon, 2005), but little is known about survival in MTS.
  5 in total

Review 1.  Muir-Torre syndrome.

Authors:  Giovanni Ponti; Maurizio Ponz de Leon
Journal:  Lancet Oncol       Date:  2005-12       Impact factor: 41.316

2.  PMS2 mutations in childhood cancer.

Authors:  Michel De Vos; Bruce E Hayward; Ruth Charlton; Graham R Taylor; Adam W Glaser; Susan Picton; Trevor R Cole; Eamonn R Maher; Carole M E McKeown; Jill R Mann; John R Yates; Diana Baralle; Julia Rankin; David T Bonthron; Eamonn Sheridan
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

Review 3.  Familial adenomatous polyposis.

Authors:  Polymnia Galiatsatos; William D Foulkes
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

4.  Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC.

Authors:  N Hoogerbrugge; R Willems; H J Van Krieken; L A Kiemeney; M Weijmans; F M Nagengast; N Arts; H G Brunner; M J L Ligtenberg
Journal:  Clin Genet       Date:  2003-01       Impact factor: 4.438

5.  Germline truncating mutations in both MSH2 and BRCA2 in a single kindred.

Authors:  I Thiffault; N Hamel; T Pal; S McVety; V A Marcus; D Farber; S Cowie; J Deschênes; W Meschino; F Odefrey; D Goldgar; T Graham; S Narod; A K Watters; E MacNamara; D Du Sart; G Chong; W D Foulkes
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.